Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vertex Pharmaceuticals (NQ: VRTX ) 495.89 +2.54 (+0.51%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Vertex Pharmaceuticals < Previous 1 2 ... 8 9 10 11 12 13 14 15 16 ... 51 52 Next > The Best Stock to Invest $1,000 in Right Now January 17, 2024 This stock has what it takes to be a big winner. Via The Motley Fool Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock January 16, 2024 Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering. Via Investor's Business Daily Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia January 16, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire 10 Health Care Stocks With Whale Alerts In Today's Session January 16, 2024 Via Benzinga Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals January 11, 2024 Via Benzinga A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 16 Analysts January 09, 2024 Via Benzinga A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings January 09, 2024 Via Benzinga $1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today January 08, 2024 Via Benzinga Here's Why CRISPR Therapeutics Stock Rose 54% Last Year January 15, 2024 Key regulatory developments sent this biotech stock higher. Via The Motley Fool Down 88%, Could Editas Medicine Be a Good Investment Now? January 15, 2024 The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles. Via The Motley Fool My 3 Highest-Conviction Growth Stocks to Buy in 2024 January 14, 2024 Simply put, these stocks inspire confidence. Via The Motley Fool 3 Growth Stocks to Buy That Could Be Massive Long-Term Winners January 14, 2024 These stocks appear to have what it takes to keep up their winning ways. Via The Motley Fool 3 Unstoppable Stocks to Buy in 2024 January 13, 2024 These stocks appear to be on a clear path to continued growth. Via The Motley Fool Is Vertex Pharmaceuticals Stock a Buy Now? January 06, 2024 The biotech's prospects keep improving. Via The Motley Fool Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week January 13, 2024 These companies could stand out thanks to game-changing technology. Via The Motley Fool Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' January 12, 2024 On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE: UBER) shares hit an all-time high on Thursda Via Benzinga 3 Stocks to Buy in the Booming Field of Gene Editing January 11, 2024 As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains. Via InvestorPlace Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)? January 11, 2024 Reasonable growth and debt and a high ROIC for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX). Via Chartmill 10 Health Care Stocks With Whale Alerts In Today's Session January 10, 2024 Via Benzinga 2 Red Flags for Bluebird Bio Stock January 10, 2024 The biotech's struggles may continue. Via The Motley Fool These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That Trend January 10, 2024 These winners seem likely to keep up their winning ways. Via The Motley Fool Topics Stocks Exposures US Equities Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia January 09, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire 2 low-priced gene therapy stocks to speculate on January 08, 2024 Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe Via MarketBeat Exposures Product Safety 5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday January 08, 2024 The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. Via Benzinga The Ultimate Growth Stock to Buy With $1,000 Right Now January 08, 2024 The stock, trading for about $60, has plenty of room to run. Via The Motley Fool Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings January 07, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire 5 Top Stocks to Buy in January January 07, 2024 Start the year off right by investing in these quality businesses. Via The Motley Fool Investing Trends to Follow in 2024 January 06, 2024 We've also got Motley Fool co-founder Tom Gardner sharing an investing lesson from last year and a stock for this one. Via The Motley Fool Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. Via Investor's Business Daily 2 Biotech Stocks With Huge Catalysts in 2024 January 05, 2024 Important clinical-trial readouts on the way could send these stocks soaring in early 2024. Via The Motley Fool < Previous 1 2 ... 8 9 10 11 12 13 14 15 16 ... 51 52 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.